CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2005-01-19): US FDA warns about risks of Boehringer AIDS drug


US FDA warns about risks of Boehringer AIDS drug

Last Updated: 2005-01-19 17:06:27 -0400 (Reuters Health)

WASHINGTON (Reuters) - U.S. health officials on Wednesday warned the public they had received reports of liver toxicity and deaths related to Boehringer Ingelheim's AIDS drug, Viramune (nevirapine).

The Food and Drug Administration said doctors should weigh the risks and benefits before prescribing nevirapine.

"In spite of the potential for serious and life-threatening liver toxicity and skin rashes with nevirapine, there are multiple reasons why nevirapine remains an important part of an HIV treatment regimen (for many people)," the FDA said in a statement.

Cases of liver damage that produce symptoms such as a rash, fever or other symptoms are more common with Viramune than with other HIV-fighting drugs, the FDA said. Some instances have been fatal.

No serious or fatal liver toxicity has been reported after a single Viramune dose, the FDA said. In many developing countries, a single dose of the drug is given to pregnant women to prevent mother-to-child transmission of HIV.

Boehringer Ingelheim is a privately held company based in Germany. A company spokeswoman could not immediately be reached for comment.

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Live CME Meetings
Slide Library
Abstract Library
CLDF Follow Us
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Regional Map
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2015 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.